Efficacy of Brodalumab vs Ustekinumab by Prior TNFα Inhibitor Exposure: Post hoc Analysis of Two Phase 3 Psoriasis Studies

Alan Menter; Erin  Boh; George Lewitt; Abby  Jacobson

doi:10.25251/skin.5.supp.51

Alan Menter

Baylor University Medical Center, Dallas, TX

Erin Boh

Tulane University School of Medicine

George Lewitt

Illinois Dermatology Institute, Chicago, IL

Abby Jacobson

Ortho Dermatologics

Keywords

brodalumab, psoriasis, post hoc phase 3 study analysis

Abstract

N/A

References

1. Siliq [package insert]. Bausch Health US, LLC; 2017. 2. Lebwohl et al. N Engl J Med. 2015;373:1318-1328.

Poster PDF

Published

Nov 5, 2021

DOI https://doi.org/10.25251/skin.5.supp.51

How to Cite

Menter, A., Boh, E. ., Lewitt, G., & Jacobson, A. . (2021). Efficacy of Brodalumab vs Ustekinumab by Prior TNFα Inhibitor Exposure: Post hoc Analysis of Two Phase 3 Psoriasis Studies. SKIN The Journal of Cutaneous Medicine, 5(6), s51. https://doi.org/10.25251/skin.5.supp.51

Issue

Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)

Section

Poster Presentations from FC21 Dermatology Conference®: Psoriasis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Jerry Bagel, Yipeng Wang, Paul Montgomery, III, Christian Abaya, Eric Andrade, Courtney Boyce, Tatiana Tomich, Byung-In Lee, David Pariser, Alan Menter, Tobin Dickerson, A Machine Learning-Based Test for Predicting Response to Psoriasis Biologics , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Richard Warren, Howard Sofen, Shinichi Imafuku, Jacek Szepietowski, Andrew Blauvelt, Lynda Spelman, Jessica Toms, Alex Buck, Subhashis Banerjee, Alan Menter, Deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Alan Menter, Andrew Blauvelt, Bruce Strober, Matthew Colombo, Renata Kisa, Sudeep Kundu, Subhashis Banerjee, Craig Leonardi, Deucravacitinib (BMS-986165), an Oral, Allosteric Tyrosine Kinase 2 Inhibitor, Reduces Body Surface Area Involvement and Improves Quality of Life in Patients With Psoriasis , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Linda Stein Gold, Mark Lebwohl, Neal Bhatia, Douglas DiRuggiero, Abby Jacobson, Radhakrishnan Pillai, Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Mark Lebwohl, Richard B. Warren, Howard Sofen, Shinichi Imafuku, Carle Paul, Jacek C. Szepietowski, Lynda Spelman, Thierry Passeron, Elizabeth Colston, Lauren Hippeli, Andrew Napoli, Renata M. Kisa, Subhashis Banerjee, Alan Menter, Diamant Thaçi, Andrew Blauvelt, Deucravacitinib long-term efficacy with continuous treatment in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Linda Stein Gold, Jonathan S Weiss, Lawrence Green, Leon Kircik, Lauren Miller, Abby Jacobson, Susan Harris, Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% (HP/TAZ) Lotion in Patients with Baseline Body Surface Area of 6 -12% , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)
Carle Paul, Craig Leonardi, Alan Menter, Kristian Reich, Linda Stein Gold, Richard B Warren, Anders Moller, Mark Lebwohl, Calcipotriol Plus Betamethasone Dipropionate Foam is Effective in Patients with Moderate-to-Severe Psoriasis: Post-Hoc Analysis of the PSO-ABLE Study , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters Presented at 2018 Winter Clinical Dermatology Conference®-Hawaii
Mark Lebwohl, Andrew Blauvelt, Alan Menter, Kim Papp, Abby Jacobson, Long-term Efficacy, Safety, and Patient-Reported Outcomes in a Phase 2 Study of Brodalumab , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
Lawrence Green, Jerry Bagel, George Han, Abby Jacobson, Martha Sikes, Halobetasol Propionate 0.01% Lotion for Plaque Psoriasis: Epidermal Permeation, Efficacy, and Safety , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Mark Lebwohl, Kim A Papp, Jashin J Wu, Andrew Blauvelt, Alan Menter, Shipra Rastogi, Radhakrishnan Pillai, Robert Israel, Neuropsychiatric Adverse Events in Brodalumab Psoriasis Studies , SKIN The Journal of Cutaneous Medicine: Vol. 1 (2017): Supplemental Issue: Scientific Posters Presented at 2017 Fall Clinical Dermatology Conference®-Las Vegas

1 2 3 4 > >>

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Most read articles by the same author(s)